Isis Pharmaceuticals Articles
GSK pays $7.5 million milestone to Isis Pharma under antisense deal; says FDA accepts Anoro Ellipta NDA
20 February 2013
Makers of Kynamro and Fanaptum to appeal negative CHMP opinions
17 December 2012
Isis on a roll as it signs another licence deal
12 December 2012
Biogen Idec and Isis Pharma in up to $230 million antisense deal
11 December 2012
GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab
6 November 2012
FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro
19 October 2012
Genzyme and Isis file Kynamro NDA in USA
2 April 2012
Isis Pharma could earn $299 million from Biogen Idec deal
5 January 2012
Isis sees Kynamro delay; adds new drugs to pipeline
15 December 2011
Santaris prevails in patent battle with Isis Pharma
30 November 2011
Genentech and Seattle Genetics expand collaboration; Genzyme/Isis cholesterol candidate meets Ph III goals
5 August 2010
GlaxoSmithKline pays $15 million to exercise option on Anacor’s novel antibiotic; and $5 million milestone to Isis Pharma
1 August 2010
Teva gains access to OncoGenex cancer drug in up to $430 deal including stake in the US firm
22 December 2009
Genzyme and Isis meet cholesterol trial endpoint
26 May 2009
Alnylam's loss rockets on R&D expenses
11 May 2009
Isis Pharma good buy in tough market; Zacks
9 April 2009
Regulus raises $20M
16 March 2009
Genzyme/Isis begin three mipomersen trials
19 January 2009
Novosom gets rights to Isis' targeted CD40 mRNA
1 September 2008
Amgen initiates Ph III Aranesp study in HF
18 August 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Abbott invests another $20M in Isis' Ibis unit
7 July 2008
Isis advised on new drug's approval path
5 May 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
Isis gets $2M as B-MS selects first PCSK9 blocker
14 April 2008
Isis in possible $1.5B deal with Genzyme
14 January 2008
Altair to commercialize Isis' antisense drugs
22 October 2007
Isis Pharma cuts 2007 net operating loss prediction
15 October 2007
Isis awarded $1.5M grant for RNAi development
8 October 2007
Isis pays $120M for Symphony GenIsis
8 October 2007
Alnylam and Isis form Regulus Thera JV
17 September 2007
Strategic alliance for Archemix and Isis
13 August 2007
OGX-011 shows promise in Ph II prostate cancer study
6 August 2007
Isis benefits from Alnylam/Roche deal
26 July 2007
Alnylam gets milestone from Isis
9 July 2007
Novosom acquires option form Isis Pharma
16 April 2007
Isis antisense drug cuts atherogenic lipids
2 April 2007
Isis Pharma recruits Jeffrey Jonas as exec VP
5 February 2007
Isis completes $125M financing
29 January 2007
Isis Pharma to sell $125M of notes
22 January 2007
Isis Pharma/Symphony enter $75M accord
17 April 2006
Oral ISIS 301012 yields encouraging Ph I data
13 February 2006
Isis receives milestone payment from Eli Lilly
13 February 2006
Isis claims $4M from Novartis/Alnylam accord
19 September 2005
Isis grants iCo rights to ISIS 13650
5 September 2005
Isis and Lilly extend antisense R&D accord
15 August 2005
OncoGenex starts treating in Ph II trial of anticancer drug
15 August 2005
Isis Pharma gets $1.1M contract from US govt
1 August 2005
OncoGenex starts first Ph II trial of cancer drug
25 July 2005
Good Ph II results for ISIS' antidiabetic
27 June 2005
Isis' cholesterol drug sees good results
20 June 2005
Antisense drugs get thumbs-up from Isis
9 May 2005
Isis to shares Macugen royalties for $24 M
10 January 2005
Eyetech due $90M as FDA clears Macugen
10 January 2005
Isis' alicaforsen fails in Crohn's disease trials
13 December 2004
Isis/Lilly's LY2181308 advances to clinic
22 November 2004
$10M US govt contract for Isis Pharma
11 October 2004
Isis selects antisense drug for development
27 September 2004
Lilly licenses antisense drug from Isis
27 September 2004
Eyetech sees losses grow on Macugen development costs
2 August 2004
Isis earns $1M milestone on Macugen filing
28 June 2004
Isis acquires Elan's share of Orasense and HepaSense
14 June 2004
Positive data from PI trial of ATL-1102 for MS
14 June 2004
Isis in strategic RNAi alliance with Alnylam
22 March 2004
Isis' 104838 shows promise for RA
19 January 2004
Isis starts Ph I trial for ISIS 301012
5 January 2004
Amersham Biosciences' OligoProcess assists Isis Pharma
15 September 2003
Isis and Lilly renegotiate Affinitak production deal
16 June 2003
Alicaforsen benefits pouchitis patients
2 June 2003
Losses up at Isis as revenues slump
19 May 2003
Isis starts trials of diabetes compound
19 May 2003
Underlying growth beats forecasts at Lilly
28 April 2003
Isis gets milestone in Lilly collaboration
28 April 2003
Hybridon swings to profit in 2002
21 April 2003
Isis Pharma starts second Ph II trial in colitis
14 April 2003
OncoGenex starts second cancer trial
14 April 2003
Isis/Lilly's Affinitak disappoints in Ph III
24 March 2003
Isis Pharma's 2002 revenues leap 51%
17 February 2003
Isis and atugen in license accord
27 January 2003
Isis re-aquires ISIS 113715 from Merck & Co
6 January 2003
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
